M. Aboud

发表

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use

Kimberly Smith, Melissa Crawford, J. V. van Wyk, 2019, Journal of acquired immune deficiency syndromes.

Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.

Kimberly Smith, M. Aboud, V. Vannappagari, 2019, Current HIV research.

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.

Kimberly Smith, M. Aboud, R. Kaplan, 2019, The Lancet. Infectious diseases.

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection

J. Rockstroh, P. Cahn, A. Antinori, 2021, AIDS.

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health

G. McComsey, M. Aboud, B. Wynne, 2017, AIDS.

Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review

J. Gatell, M. Aboud, V. Vannappagari, 2019, Antiviral therapy.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study

J. Gatell, Kimberly Smith, M. Aboud, 2019, Journal of Infection and Public Health.

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

S. Walmsley, C. Orrell, Kimberly Smith, 2017, The lancet. HIV.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

Psychiatric Symptoms in Patients Receiving Dolutegravir

A. Winston, M. Aboud, V. Vannappagari, 2017, Journal of acquired immune deficiency syndromes.

Clinical Utility of Genotypic Resistance Tests for HIV-1-Infected Patients with Low-Level Virological Failure

M. Aboud, R. Kulasegaram, A. Elgalib, 2010, Journal of Clinical Microbiology.

Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

J. Lake, M. Aboud, B. Wynne, 2017, Antiviral therapy.

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use

Kimberly Smith, Melissa Crawford, M. Aboud, 2019, Journal of acquired immune deficiency syndromes.

Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies

J. Rockstroh, P. Cahn, A. Antinori, 2020, Journal of Infection and Public Health.

Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.

B. Taiwo, B. Berzins, Kimberly Smith, 2019, The Journal of antimicrobial chemotherapy.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Dolutegravir-Based Antiretroviral Therapy for Patients Co-Infected with Tuberculosis and Hiv: A Multicenter, Noncomparative, Open-Label, Randomized Trial.

K. Dooley, E. Ticona, O. Sued, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial

K. Dooley, E. Ticona, O. Sued, 2019 .

Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study

A. Wierzbicki, M. Aboud, B. Peters, 2010, International journal of clinical practice.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

D. Kuritzkes, J. Schapiro, J. Polli, 2021, AIDS.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

C. Hung, F. Castelli, M. Aboud, 2018, The Lancet.

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

J. Routy, S. De Wit, Kimberly Smith, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Insulin resistance and HIV infection: a review

M. Aboud, B. Peters, R. Kulasegaram, 2007, International journal of clinical practice.

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

Keith Nangle, Kimberly Smith, M. Aboud, 2021, Antimicrobial agents and chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

D. Podzamczer, C. Orkin, Kimberly Smith, 2019, The lancet. HIV.

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

J. Rockstroh, P. Cahn, A. Antinori, 2019, Journal of acquired immune deficiency syndromes.

Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)

J. Routy, J. V. Wyk, M. Aboud, 2020 .

Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies

C. Hung, J. Slim, J. Eron, 2019, Journal of Infection and Public Health.

The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study

A. Wierzbicki, M. Aboud, B. Peters, 2011, Current medical research and opinion.

Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database

K. Mounzer, M. Aboud, V. Vannappagari, 2018, Therapeutic Advances in Drug Safety.

Etravirine plasma levels in a patient with decompensated liver disease

D. Back, M. Aboud, R. Kulasegaram, 2009, AIDS (London).

Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.

C. Hung, J. Slim, J. Eron, 2020, Journal of acquired immune deficiency syndromes.

Antiretroviral therapy and liver disorders in the OPERA® cohort

K. Mounzer, M. Aboud, V. Vannappagari, 2020, Therapeutic advances in drug safety.

Dolutegravir/rilpivirine 2-drug regimen comparable to commonly prescribed 3-drug regimens up to 18-months in a real-world setting

R. Weber, M. Aboud, V. Vannappagari, 2022, Antiviral Therapy.

Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by

Kimberly Smith, M. Aboud, B. Wynne, 2016 .

Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study

A. Wierzbicki, M. Aboud, B. Peters, 2010, International journal of clinical practice.